Cybin Announces CDN$20 Million Bought Deal Offering Jan 18 • 4 min read Cybin Inc. announced that it has entered into an agreement with Canaccord Genuity Corp. to purchase 8,900,000 units of the company at a price of CDN$2.25 per unit for aggregate gross proceeds of CDN$20,025,000.
Seelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder Jan 15 • 4 min read Seelos Therapeutics, Inc. announced dosing of the first patients in its registrational Proof of Concept study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder.
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience Jan 14 • 3 min read MindMed announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer.
Novamind Expands Psychedelic Medicine Access in Utah Jan 13 • 2 min read Novamind Inc. announced the expansion and optimization of its Cedar Psychiatry clinic in Layton, Utah.
PharmaTher Approved to Trade on the OTCQB Venture Market Jan 13 • 2 min read Newscope Capital Corporation, who through its wholly-owned subsidiary, PharmaTher Inc., announced that its common shares have been approved for trading on the OTCQB® Venture Market effective today.